Daytrading, Eminis, Forex trading, Swing Trading TOP STORY - 528131

T Cell Triumph? - Opexa Reports Encouraging Data From Early-stage Clinical Trial With Tovaxin For Multiple Sclerosis

Tuesday, Opexa Therapeutics Inc. (OPXA | charts | news | PowerRating) reported positive results from an early stage dose escalation clinical trial of the investigational T-cell vaccine, Tovaxin, for multiple sclerosis. T cell is a type of white blood cell that attacks virus-infected cells, foreign cells, and cancer cells.

In the one-year, 10-subject Phase I/II clinical trial, patients received one of the three dosage levels of Tovaxin over a period of 20 weeks and were monitored for an additional 32 weeks. The clinical results of the trial demonstrated that Tovaxin therapy achieved a 90% reduction in annualized relapse rate in subjects who received one of the three doses. There were no severe adverse reactions related to T-cell vaccination for none of the dosage levels.

The Tovaxin Phase IIb clinical study known as TERMS will include 150 patients and will evaluate the efficacy, safety and tolerability of the Tovaxin T- cell vaccination with clinically isolated syndrome and relapsing-remitting multiple sclerosis patients.

In February 2007, the company reported encouraging results from a clinical trial, evaluating its T-cell vaccine in patients with rheumatoid arthritis.

http://www.tradingmarkets.com/.site/news/TOP STORY/528131/